Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
6.62
-0.37 (-5.29%)
Mar 31, 2025, 1:29 PM EDT - Market open
Immunome Employees
Immunome had 118 employees as of December 31, 2024. The number of employees increased by 63 or 114.55% compared to the previous year.
Employees
118
Change (1Y)
63
Growth (1Y)
114.55%
Revenue / Employee
$76,619
Profits / Employee
-$2,482,737
Market Cap
575.61M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | 39 | 16 | 69.57% |
| Dec 31, 2020 | 23 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMNM News
- 11 days ago - Immunome Reports Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 21 days ago - Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC - Business Wire
- 24 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Immunome to Present at Upcoming March Conferences - Business Wire
- 2 months ago - Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - Business Wire
- 2 months ago - Immunome Can Take The Fight To Competitors With Varegacestat - Seeking Alpha
- 2 months ago - Immunome Announces Pricing of Upsized Public Offering of Common Stock - Business Wire
- 2 months ago - Immunome Announces Proposed Public Offering of Common Stock - Business Wire